Analyst consensus rating

Aktis Oncology Analyst Rating: Strong Buy

Direct answer

Aktis Oncology's consensus rating is Strong Buy.

8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $35.88.
Forecast evidence checked November 17, 2026.

Get free Aktis Oncology email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$16.16
Average price target
$35.88
High price target
$40.00
Low price target
$33.00
Low target gap
+104.2%
Target upside
+122%
High target gap
+147.5%
Target range width
43.3%
Consensus rating
Strong Buy
Analysts
8
Evidence date
November 17, 2026
Valid through
November 24, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Aktis Oncology?

Aktis Oncology has a verified Strong Buy consensus. The same dataset has an average price target of $35.88.

How far are Aktis Oncology's low and high targets from the recorded price?

The low target implies +104.2%, while the high target implies +147.5%.

How many analysts are included in Aktis Oncology's consensus?

The verified consensus includes 8 analysts.

How is Aktis Oncology's target upside or downside calculated?

The average target of $35.88 is divided by the recorded price of $16.16, then one is subtracted to produce +122%. This does not guarantee a future return.

When was Aktis Oncology's analyst forecast verified?

The data was verified on 2026-11-17. The dataset is valid through 2026-11-24.